Doctors have already begun reducing radiation treatment for women at low risk of recurrence or spread of the disease. A new study finds that some women at greater risk can safely avoid radiation. By ...
Targeted treatments, including antibody-drug conjugates and immunotherapy agents, are now standard of care for breast cancer, but there are limited data on the safety of combining these newer agents ...
Results from a retrospective cohort study analyzing patients with breast cancer bolster reports of an association between radiation therapy and subsequent risks of skin cancers. Radiation therapy in ...
Patients with TP53 germline variants have an increased risk of secondary sarcoma post-radiation therapy. The 15-year risk of sarcoma for TP53 pathogenic variant carriers is 8.8%, higher than the ...
CANCER TREATMENT CAN BE GRUELING, AND IT CAN ALSO MAKE FOR LONG DAYS. A NEW STUDY, THOUGH, SHOWS HIGHER DOSES OF RADIATION GIVEN OVER FEWER SESSIONS WAS AS EFFECTIVE AS BEING GIVEN LOWER DOSES OVER ...
a team of researchers at Cedars-Sinai analyzed the combination of pembrolizumab, an immunotherapy drug known as Keytruda, with radiation therapy to identify patient response and understand changes in ...
Radiation therapy combined with Keytruda increased T cell infiltration in HR+ and HER2-negative breast cancer, enhancing immune response. High-dose radiation with Keytruda led to increased ...
A single, targeted high dose of radiation delivered before other treatments could completely eradicate tumors in most women with early-stage, operable hormone-positive breast cancer, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results